 Around 15 of the United Kingdom UK have asthma, of these, 10-20 have asthma which is difficult to control using current therapies and with high levels of morbidity resulting. These patients consume 50-60 of the UK healthcare costs of asthma and as such, there is much interest in developing novel treatments for this group. 